Table 2 Post matching characteristics

p

p

Age, median (IQR)

65.6

(57.3–76.7)

60.1

(51.1–68.2)

0.119

65.5

(56.0–74.7)

71.1

(61.2–75.5)

0.103

Male, n (%)

30

(50.8)

65

(55.1)

0.709

32

(57.1)

62

(55.3)

0.956

Disease stage, n (%)

0.671

0.252

 I-II

17

(28.8)

29

(24.6)

24

(42.9)

60

(53.5)

 III

42

89

32

52

pT stage, n (%)

0.442

0.397

 T1–2

8

(13.6)

23

(19.5)

10

(17.9)

28

(25.0)

 T3–4

51

95

46

84

pN stage, n (%)

0.288

0.208

 N0–1

24

(40.7)

37

(31.3)

26

(46.4)

65

(58.0)

 N2–3

35

81

30

47

ECOG ≥ 2, n (%)

4

(6.8)

9

(7.6)

0.919

4

(7.1)

12

(10.7)

0.642

HER2-positive, n (%)

3

(5.1)

8

(6.8)

0.945

4

(7.1)

10

(8.9)

0.921

Tumor at GEJ, n (%)

4

(6.8)

5

(4.2)

0.717

4

(7.1)

5

(4.5)

0.716

Lauren histology type, n (%)

0.232

0.781

 Intestinal

23

(39.0)

34

(28.8)

21

(37.5)

46

(41.1)

 Diffuse

24

(40.7)

67

(56.8)

23

(41.1)

48

(42.9)

 Mixed

11

17

11

15

 Others^a

1

0

1

3

Borrmann classification, n (%)

0.945

0.676

 Infiltrative

47

(60.7)

95

(70.5)

41

(73.2)

77

(68.8)

 Non-infiltrative

12

23

15

35

LVI (+), n (%)

43

(72.9)

96

(81.4)

0.271

39

(69.6)

72

(64.3)

0.604

Median CEA ng/mL, (IQR)

1.8

(1.3–2.8)

2.4

(1.3–3.5)

0.213

1.9

(1.3–2.6)

2.1

(1.5–4.4)

0.072

H. pylori infection, n (%)

9

(15.3)

34

(28.8)

0.072

10

(17.9)

23

(20.5)

0.837

 S-1

59

–

56

–

 PFL

–

71

–

–

 XELOX/FOLFOX

–

47

–

–